WO2002089848A3 - Methode de traitement du diabete - Google Patents

Methode de traitement du diabete Download PDF

Info

Publication number
WO2002089848A3
WO2002089848A3 PCT/US2002/011847 US0211847W WO02089848A3 WO 2002089848 A3 WO2002089848 A3 WO 2002089848A3 US 0211847 W US0211847 W US 0211847W WO 02089848 A3 WO02089848 A3 WO 02089848A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
medicament
manufacture
treatment
type
Prior art date
Application number
PCT/US2002/011847
Other languages
English (en)
Other versions
WO2002089848A2 (fr
Inventor
Emanuele Sher
Original Assignee
Lilly Co Eli
Emanuele Sher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Emanuele Sher filed Critical Lilly Co Eli
Priority to JP2002586980A priority Critical patent/JP2004530680A/ja
Priority to EP02769268A priority patent/EP1390072A2/fr
Priority to AU2002307327A priority patent/AU2002307327A1/en
Priority to CA002446161A priority patent/CA2446161A1/fr
Publication of WO2002089848A2 publication Critical patent/WO2002089848A2/fr
Publication of WO2002089848A3 publication Critical patent/WO2002089848A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une méthode de traitement du diabète consistant à administrer à un patient une dose efficace d'un potentialisateur approprié du récepteur AMPA.
PCT/US2002/011847 2001-05-04 2002-04-22 Methode de traitement du diabete WO2002089848A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002586980A JP2004530680A (ja) 2001-05-04 2002-04-22 ２型糖尿病治療薬製造のためのａｍｐａ受容体増強物質の使用
EP02769268A EP1390072A2 (fr) 2001-05-04 2002-04-22 Methode de traitement du diabete
AU2002307327A AU2002307327A1 (en) 2001-05-04 2002-04-22 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
CA002446161A CA2446161A1 (fr) 2001-05-04 2002-04-22 Methode de traitement du diabete

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28889101P 2001-05-04 2001-05-04
US60/288,891 2001-05-04

Publications (2)

Publication Number Publication Date
WO2002089848A2 WO2002089848A2 (fr) 2002-11-14
WO2002089848A3 true WO2002089848A3 (fr) 2002-12-12

Family

ID=23109101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/011847 WO2002089848A2 (fr) 2001-05-04 2002-04-22 Methode de traitement du diabete

Country Status (5)

Country Link
EP (1) EP1390072A2 (fr)
JP (1) JP2004530680A (fr)
AU (1) AU2002307327A1 (fr)
CA (1) CA2446161A1 (fr)
WO (1) WO2002089848A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579575A (zh) * 2013-06-13 2016-05-11 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5014334B2 (ja) * 2005-10-06 2012-08-29 イーライ リリー アンド カンパニー Ａｍｐａ受容体増強剤
DE102008047461A1 (de) * 2008-09-17 2010-04-15 Dr.Ing.H.C.F.Porsche Aktiengesellschaft Verbindungseinrichtung zum Verbinden von Verkleidungselementen
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
US10882837B2 (en) * 2017-01-24 2021-01-05 Alphala Co., Ltd. Amide compounds and use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459138A (en) * 1993-03-26 1995-10-17 Adir Et Compagnie Pyridothiadiazines
WO1998033496A1 (fr) * 1997-02-04 1998-08-06 Eli Lilly And Company Derives sulfamides
WO2000006148A1 (fr) * 1998-07-31 2000-02-10 Eli Lilly And Company Sulfamides
WO2000006158A1 (fr) * 1998-07-31 2000-02-10 Eli Lilly And Company Derives de sulfamide heterocyclyles
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
WO2000066546A2 (fr) * 1999-04-30 2000-11-09 Eli Lilly And Company Derives de monofluoralkyle
WO2001042203A1 (fr) * 1999-12-08 2001-06-14 Eli Lilly And Company Derives de sulfonamide de cyclopentyle
WO2001089510A2 (fr) * 2000-05-24 2001-11-29 Eli Lilly And Company Methode de traitement de l'obesite

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459138A (en) * 1993-03-26 1995-10-17 Adir Et Compagnie Pyridothiadiazines
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
WO1998033496A1 (fr) * 1997-02-04 1998-08-06 Eli Lilly And Company Derives sulfamides
WO2000006148A1 (fr) * 1998-07-31 2000-02-10 Eli Lilly And Company Sulfamides
WO2000006158A1 (fr) * 1998-07-31 2000-02-10 Eli Lilly And Company Derives de sulfamide heterocyclyles
WO2000066546A2 (fr) * 1999-04-30 2000-11-09 Eli Lilly And Company Derives de monofluoralkyle
WO2001042203A1 (fr) * 1999-12-08 2001-06-14 Eli Lilly And Company Derives de sulfonamide de cyclopentyle
WO2001089510A2 (fr) * 2000-05-24 2001-11-29 Eli Lilly And Company Methode de traitement de l'obesite

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERNARD PIROTTE ET AL.: "4H-1,2,4-Pyridothiadiazine 1,1-Dioxides and 2,3-Dihydro-4H-1,2,4-pyridothiadiazine 1,1-Dioxides Chemically Related to Diazoxide and Cyclothiazide as Powerful Positive Allosteric Modulators of (R/S)-2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic Acid Receptors: Design, Synthesis, Pharmacology,", J.MED.CHEM., vol. 41, no. 16, 30 July 1998 (1998-07-30), pages 2946 - 2959, XP001094745 *
BIGGE C F ET AL: "AMPA RECEPTOR AGONISTS, ANTAGONISTS AND MODULATORS: THEIR POTENTIALFOR CLINICAL UTILITY", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 7, no. 10, 1997, pages 1099 - 1114, XP001037439, ISSN: 1354-3776 *
NOBUA INAGAKI ET AL.: "Expression and role of ionotropic glutamate receptors in pancreatic islet cells", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, vol. 9, no. 8, May 1995 (1995-05-01), USA, pages 686 - 691, XP001098407 *
ZARRINMAYEH, HAMIDEH ET AL: "[3H]N-2-(4-(N-benzamido)phenyl)propyl-2- propanesulfonamide: a novel AMPA receptor potentiator and radioligand", JOURNAL OF MEDICINAL CHEMISTRY (2001), 44(3), 302-304, vol. 44, no. 3, 1 February 2001 (2001-02-01), pages 302 - 304, XP001098144 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579575A (zh) * 2013-06-13 2016-05-11 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法

Also Published As

Publication number Publication date
EP1390072A2 (fr) 2004-02-25
AU2002307327A1 (en) 2002-11-18
WO2002089848A2 (fr) 2002-11-14
JP2004530680A (ja) 2004-10-07
CA2446161A1 (fr) 2002-11-14

Similar Documents

Publication Publication Date Title
WO2002096363A3 (fr) Methode de traitement de maladies fibreuses ou d'autres indications
WO2001027119A3 (fr) Bibliotheque de substances contenant des imidazo-5-yl-amines bicyciques et/ou des imidazo-3-yl-amines bicycliques
WO1999044581A3 (fr) Composition pharmaceutique de topiramate
MXPA03007712A (es) Sales farmaceuticas.
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
WO2001001973A3 (fr) Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation
WO2002060389A3 (fr) Procede permettant de traiter l'insuffisance cardiaque chronique et/ou des taux de cholesterol eleves par l'acide 3,5-diiodothyropropionique et procede de preparation de ce dernier
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
MXPA03007262A (es) Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias.
WO2001078711A3 (fr) Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
WO2002076472A3 (fr) Combinaisons pharmaceutiques destinees au traitement du cancer
WO2004043341A3 (fr) Traitement pour choc hémorragique
WO2003039539A3 (fr) Utilisation d'antagonistes du recepteur de l'endotheline dans le traitement de maladies tumorales
WO2002096362A3 (fr) Methode de traitement de maladies fibreuses ou d'autres indications
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2002089848A3 (fr) Methode de traitement du diabete
WO2004087880A3 (fr) Composes et leur utilisation dans le traitement du diabete et troubles connexes
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO2000004012A8 (fr) COMPOSES SPECIFIQUES DU RECEPTEUR ADRENERGIQUE α1d HUMAIN ET SES UTILISATIONS
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine
WO2001089510A3 (fr) Methode de traitement de l'obesite
WO2003020221A3 (fr) Methode de traitement d'une maladie cancereuse
WO2002074034A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de l'endotheline
WO2003059395A3 (fr) Antisens diriges contre le csf-1 humain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002769268

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2446161

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002586980

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002769268

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002769268

Country of ref document: EP